Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-07-25

Clinical Trial Update: Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating MGTA-145 in combination with Plerixafor for sickle cell disease was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • MGTA-145
  • Plerixafor (Plerixafor)

Snippet

Sponsor: Ensoma | Conditions: Sickle Cell Disease | Phase 2 | Status: TERMINATED | Results posted: 2025-07-25